Fig. 4 | Scientific Reports

Fig. 4

From: Clinical outcomes of conversion surgery following neoadjuvant chemoimmunotherapy in potentially resectable stage IIIA/IIIB non-small cell lung

Fig. 4

Representative cases of MPR patient and non-MPR patients with the results of IHC staining of TIME immune markers at baseline and after neoadjuvant treatment, respectively. (A) Comparison of infiltrating CD4 + TILs between the MPR group (n = 40) and the non-MPR group (n = 29) before and after treatment. (B) Comparison of infiltrating CD8 + TILs between the MPR group (n = 40) and the non-MPR group (n = 29) before and after treatment. (C) Comparison of the expression of PD-L1 between the MPR group (n = 40) and the non-MPR group (n = 29) before and after treatment. (D) Comparison of infiltrating CD4+, CD8 + TILs and expression of PD-L1 in all patients before and after treatment. TIME tumor immune microenvironment, TILs tumor-infiltrating lymphocytes.

Back to article page